High-sensitivity cardiac troponin T is superior to troponin I in the prediction of mortality in patients without acute coronary syndrome

Ásthildur Árnadóttir; Kirstine Roll Vestergaard; Jannik Pallisgaard; György Sölétormos; Rolf Steffensen; Jens P. Goetze; Kasper Iversen

doi:10.1016/j.ijcard.2018.01.131

High-sensitivity cardiac troponin T is superior to troponin I in the prediction of mortality in patients without acute coronary syndrome

Ásthildur Árnadóttir^*, Kirstine Roll Vestergaard, Jannik Pallisgaard, György Sölétormos, Rolf Steffensen, Jens P. Goetze, Kasper Iversen

^*Corresponding author af dette arbejde

13 Citationer (Scopus)

Abstract

Background: Differences in prevalence and prognostic information of cardiac troponin T (cTnT) and I (cTnI) concentrations in patients without acute coronary syndrome (ACS) are insufficiently investigated. High-sensitivity assays (hs-cTn) have led to an increased interest in hs-cTn for risk stratification. Here, we compare hs-cTnT and hs-cTnI in prediction of mortality patients without ACS. Method and results: Patients aged >18 years, consecutively admitted to an emergency department (ED) were included. Blood was collected at admission and later analyzed with high-sensitivity assays for cTnT (Roche) and cTnI (Siemens). Troponin concentrations were reported as normal or increased according to the clinical cut-off value of 99th percentile as defined by the manufacturer. The primary outcome was all-cause mortality. Of the 822 participants (median, 65 years [48–77]; 428 female [52%]), 239 patients died. Median follow-up time was 3.0 years [2.1–3.0]. Elevation of hs-cTn was observed in 40% (n = 345) for hs-cTnT and 8% (n = 64) for hs-cTnI, p < 0.001. The relationship between elevated hs-cTn and mortality was strong for both hs-cTnT and hs-cTnI [HR 6.0 (95%CI: 2.9–12.6) vs. 5.1 (95%CI: 1.9–13.6)].There was no difference in prognostic accuracy for short-term mortality (30 days) between hs-cTnT and hs-cTnI. However, the prognostic accuracy for long-term mortality (1080 days) was superior for hs-cTnT than for hs-cTnI [area under the receivers operating curve (AUC) 0.81 vs 0.74, p < 0.001]. Conclusion: Both hs-cTnI and hs-cTnT were predictive for all-cause mortality. Notably, hs-cTnT measurement showed superior prognostic performance in predicting long-term all-cause mortality compared with hs-cTnI.

Originalsprog	Engelsk
Tidsskrift	International Journal of Cardiology
Vol/bind	259
Sider (fra-til)	186-191
Antal sider	6
ISSN	0167-5273
DOI	https://doi.org/10.1016/j.ijcard.2018.01.131
Status	Udgivet - 2018

Adgang til dokumentet

10.1016/j.ijcard.2018.01.131

Citationsformater

High-sensitivity cardiac troponin T is superior to troponin I in the prediction of mortality in patients without acute coronary syndrome. / Árnadóttir, Ásthildur; Vestergaard, Kirstine Roll; Pallisgaard, Jannik et al.

I: International Journal of Cardiology, Bind 259, 2018, s. 186-191.

Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › peer review

@article{9faf2b3bbd3449a5a32cd2ef6326b524,

title = "High-sensitivity cardiac troponin T is superior to troponin I in the prediction of mortality in patients without acute coronary syndrome",

abstract = "Background: Differences in prevalence and prognostic information of cardiac troponin T (cTnT) and I (cTnI) concentrations in patients without acute coronary syndrome (ACS) are insufficiently investigated. High-sensitivity assays (hs-cTn) have led to an increased interest in hs-cTn for risk stratification. Here, we compare hs-cTnT and hs-cTnI in prediction of mortality patients without ACS. Method and results: Patients aged >18 years, consecutively admitted to an emergency department (ED) were included. Blood was collected at admission and later analyzed with high-sensitivity assays for cTnT (Roche) and cTnI (Siemens). Troponin concentrations were reported as normal or increased according to the clinical cut-off value of 99th percentile as defined by the manufacturer. The primary outcome was all-cause mortality. Of the 822 participants (median, 65 years [48–77]; 428 female [52%]), 239 patients died. Median follow-up time was 3.0 years [2.1–3.0]. Elevation of hs-cTn was observed in 40% (n = 345) for hs-cTnT and 8% (n = 64) for hs-cTnI, p < 0.001. The relationship between elevated hs-cTn and mortality was strong for both hs-cTnT and hs-cTnI [HR 6.0 (95%CI: 2.9–12.6) vs. 5.1 (95%CI: 1.9–13.6)].There was no difference in prognostic accuracy for short-term mortality (30 days) between hs-cTnT and hs-cTnI. However, the prognostic accuracy for long-term mortality (1080 days) was superior for hs-cTnT than for hs-cTnI [area under the receivers operating curve (AUC) 0.81 vs 0.74, p < 0.001]. Conclusion: Both hs-cTnI and hs-cTnT were predictive for all-cause mortality. Notably, hs-cTnT measurement showed superior prognostic performance in predicting long-term all-cause mortality compared with hs-cTnI.",

keywords = "Clinical studies, High-sensitivity cardiac troponin, Mortality, Survival",

author = "{\'A}sthildur {\'A}rnad{\'o}ttir and Vestergaard, {Kirstine Roll} and Jannik Pallisgaard and Gy{\"o}rgy S{\"o}l{\'e}tormos and Rolf Steffensen and Goetze, {Jens P.} and Kasper Iversen",

year = "2018",

doi = "10.1016/j.ijcard.2018.01.131",

language = "English",

volume = "259",

pages = "186--191",

journal = "International Journal of Cardiology",

issn = "0167-5273",

publisher = "Elsevier Ireland Ltd",

}

TY - JOUR

T1 - High-sensitivity cardiac troponin T is superior to troponin I in the prediction of mortality in patients without acute coronary syndrome

AU - Árnadóttir, Ásthildur

AU - Vestergaard, Kirstine Roll

AU - Pallisgaard, Jannik

AU - Sölétormos, György

AU - Steffensen, Rolf

AU - Goetze, Jens P.

AU - Iversen, Kasper

PY - 2018

Y1 - 2018

N2 - Background: Differences in prevalence and prognostic information of cardiac troponin T (cTnT) and I (cTnI) concentrations in patients without acute coronary syndrome (ACS) are insufficiently investigated. High-sensitivity assays (hs-cTn) have led to an increased interest in hs-cTn for risk stratification. Here, we compare hs-cTnT and hs-cTnI in prediction of mortality patients without ACS. Method and results: Patients aged >18 years, consecutively admitted to an emergency department (ED) were included. Blood was collected at admission and later analyzed with high-sensitivity assays for cTnT (Roche) and cTnI (Siemens). Troponin concentrations were reported as normal or increased according to the clinical cut-off value of 99th percentile as defined by the manufacturer. The primary outcome was all-cause mortality. Of the 822 participants (median, 65 years [48–77]; 428 female [52%]), 239 patients died. Median follow-up time was 3.0 years [2.1–3.0]. Elevation of hs-cTn was observed in 40% (n = 345) for hs-cTnT and 8% (n = 64) for hs-cTnI, p < 0.001. The relationship between elevated hs-cTn and mortality was strong for both hs-cTnT and hs-cTnI [HR 6.0 (95%CI: 2.9–12.6) vs. 5.1 (95%CI: 1.9–13.6)].There was no difference in prognostic accuracy for short-term mortality (30 days) between hs-cTnT and hs-cTnI. However, the prognostic accuracy for long-term mortality (1080 days) was superior for hs-cTnT than for hs-cTnI [area under the receivers operating curve (AUC) 0.81 vs 0.74, p < 0.001]. Conclusion: Both hs-cTnI and hs-cTnT were predictive for all-cause mortality. Notably, hs-cTnT measurement showed superior prognostic performance in predicting long-term all-cause mortality compared with hs-cTnI.

AB - Background: Differences in prevalence and prognostic information of cardiac troponin T (cTnT) and I (cTnI) concentrations in patients without acute coronary syndrome (ACS) are insufficiently investigated. High-sensitivity assays (hs-cTn) have led to an increased interest in hs-cTn for risk stratification. Here, we compare hs-cTnT and hs-cTnI in prediction of mortality patients without ACS. Method and results: Patients aged >18 years, consecutively admitted to an emergency department (ED) were included. Blood was collected at admission and later analyzed with high-sensitivity assays for cTnT (Roche) and cTnI (Siemens). Troponin concentrations were reported as normal or increased according to the clinical cut-off value of 99th percentile as defined by the manufacturer. The primary outcome was all-cause mortality. Of the 822 participants (median, 65 years [48–77]; 428 female [52%]), 239 patients died. Median follow-up time was 3.0 years [2.1–3.0]. Elevation of hs-cTn was observed in 40% (n = 345) for hs-cTnT and 8% (n = 64) for hs-cTnI, p < 0.001. The relationship between elevated hs-cTn and mortality was strong for both hs-cTnT and hs-cTnI [HR 6.0 (95%CI: 2.9–12.6) vs. 5.1 (95%CI: 1.9–13.6)].There was no difference in prognostic accuracy for short-term mortality (30 days) between hs-cTnT and hs-cTnI. However, the prognostic accuracy for long-term mortality (1080 days) was superior for hs-cTnT than for hs-cTnI [area under the receivers operating curve (AUC) 0.81 vs 0.74, p < 0.001]. Conclusion: Both hs-cTnI and hs-cTnT were predictive for all-cause mortality. Notably, hs-cTnT measurement showed superior prognostic performance in predicting long-term all-cause mortality compared with hs-cTnI.

KW - Clinical studies

KW - High-sensitivity cardiac troponin

KW - Mortality

KW - Survival

U2 - 10.1016/j.ijcard.2018.01.131

DO - 10.1016/j.ijcard.2018.01.131

M3 - Journal article

C2 - 29477263

AN - SCOPUS:85042199061

SN - 0167-5273

VL - 259

SP - 186

EP - 191

JO - International Journal of Cardiology

JF - International Journal of Cardiology

ER -

High-sensitivity cardiac troponin T is superior to troponin I in the prediction of mortality in patients without acute coronary syndrome

Abstract

Adgang til dokumentet

Fingeraftryk

Citationsformater